Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.

Clinical rheumatology - 1 Dec 2015

Schotte Heiko, Schmidt Hartmut, Gaubitz Markus, Drynda Susanne, Kekow Jörn, Willeke Peter, Schlüter Bernhard

Abstract excerpt

Indices prognosticating anti-tumor necrosis factor (TNF) response in patients with rheumatoid arthritis are a matter of interest. Differential outcome under anti-TNF and anti-interleukin-6 (IL-6) therapy raises the question whether genetic polymorphisms that have previously been linked to IL-6 production are associated with response to anti-TNF therapy. Fifty (50) rheumatoid arthritis (RA) patients were treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Rheumatoid

Share to Etanercept

Share to Haplotypes

Share to Interleukin-6

Share to Promoter Regions, Genetic

Share to Treatment Outcome

Source

Identifiers

PMID: 26526676
DOI: 10.1007/s10067-015-3107-7

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.PMID 26526676Read ↗

-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.Semantic proximity Read ↗

Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis.Semantic proximity Read ↗

Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.Semantic proximity Read ↗

Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses.Semantic proximity Read ↗

Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter.Semantic proximity Read ↗

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.Semantic proximity Read ↗

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Semantic proximity Read ↗

Genetic and Genomic Markers of Anti-TNF Treatment Response in Rheumatoid ArthritisSemantic proximity Read ↗

Novel IL-6 haplotypes and disease association.Semantic proximity Read ↗

Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.Semantic proximity Read ↗

Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?Semantic proximity Read ↗

Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.